Zwitterionic hydrogels for delivery of biomolecules

Patent metadata

Field	Value
Publication number	US-11311652-B2
Application number	US-201916598024-A
Country	US
Kind code	B2
Filing date	Oct 10, 2019
Priority date	Jul 8, 2014
Publication date	Apr 26, 2022
Grant date	Apr 26, 2022

Abstract

The invention provides a novel approach in which zwitterionic networks are used to sequester and deliver ionic biomolecules, such as proteins, without compromising their native conformation and bioactivity. Zwitterionic networks are designed to effectively retain and deliver ionic or polar biomolecules for guided tissue regeneration. The invention represents a conceptual advance and enables a novel strategy for the utilization of zwitterionic motifs as therapeutics delivery vehicles and tissue engineering scaffolds.

First claim

What is claimed is:

1. A method for sustained release of a protein in vivo, comprising:
placing an implant in vivo, wherein the implant consists of a crosslinked 3-dimensional zwitterionic polymer and a protein, wherein the protein is encapsulated in the crosslinked 3-dimensional zwitterionic polymer and is characterized by preserved bioactivity as sequestered; and
causing release of the encapsulated protein from the implant at a rate such that greater than 65% of the protein remains encapsulated after 24 hours, wherein the protein is characterized by preserved bioactivity as released,

wherein
the crosslinked 3-dimensional zwitterionic polymer is polymethacrylate, polyacrylate, polymethacrylamide or polyacrylamide crosslinked with poly (ethylene glycol) dimethacrylate, poly(ethylene glycol) diacrylate, ethylene glycol diacrylate or ethylene glycol dimethacrylate, and
the protein is a therapeutic osteogenic protein.

2. A method for promoting bone healing with a protein, comprising:
placing an implant in vivo, wherein the implant consists of a crosslinked 3-dimensional zwitterionic polymer and a protein, wherein the protein is encapsulated in the crosslinked 3-dimensional zwitterionic polymer and is characterized by preserved bioactivity as sequestered; and
causing release of the encapsulated protein from the implant, wherein the released protein is characterized by preserved bioactivity thereby promoting bone healing, wherein
the crosslinked 3-dimensional zwitterionic polymer is polymethacrylate, polyacrylate, polymethacrylamide or polyacrylamide crosslinked with poly (ethylene glycol) dimethacrylate, poly(ethylene glycol) diacrylate, ethylene glycol diacrylate or ethylene glycol dimethacrylate, and
the protein is a therapeutic osteogenic protein.

3. A method for treating a bone defect, comprising:
placing an implant in vivo, wherein the implant consists of a crosslinked 3-dimensional zwitterionic polymer and a protein, wherein the protein is encapsulated in the crosslinked 3-dimensional zwitterionic polymer and is characterized by preserved bioactivity as sequestered; and
causing release of the encapsulated protein from the implant to treat the bond defect, wherein the released protein is characterized by preserved bioactivity, wherein
the crosslinked 3-dimensional zwitterionic polymer is polymethacrylate, polyacrylate, polymethacrylamide or polyacrylamide crosslinked with poly (ethylene glycol) dimethacrylate, poly(ethylene glycol) diacrylate, ethylene glycol diacrylate or ethylene glycol dimethacrylate, and
the protein is a therapeutic osteogenic protein.

4. A method for performing tissue grafting or engineering, comprising:
placing a tissue grafting or engineering scaffold in vivo, wherein the tissue grafting or engineering scaffold consists of a crosslinked 3-dimensional zwitterionic polymer and a protein, wherein the protein is encapsulated in the crosslinked 3-dimensional zwitterionic polymer and is characterized by preserved bioactivity as sequestered; and
causing release of the encapsulated protein from the tissue grafting or engineering scaffold to facilitate tissue regeneration, wherein the released protein is characterized by preserved bioactivity,

wherein
the crosslinked 3-dimensional zwitterionic polymer is polymethacrylate, polyacrylate, polymethacrylamide or polyacrylamide crosslinked with poly (ethylene glycol) dimethacrylate, poly(ethylene glycol) diacrylate, ethylene glycol diacrylate or ethylene glycol dimethacrylate, and
the protein is a therapeutic osteogenic protein.

5. The method of claim 1 , wherein bioactivity of the encapsulated protein is preserved for at least nine days after sequestration.

6. The method of claim 1 , wherein the therapeutic osteogenic protein is selected from BMPs, TGF-beta, EGF, FGF, IGF-1 and VEGF.

7. The method of claim 1 , wherein the zwitterionic moiety comprises one or more selected from sulfobetaine, phosphorylcholine and carboxybetaine.

8. The method of claim 7 , wherein the zwitterionic moiety is present in the polymer as pendant groups to a polymeric backbone.

9. The method of claim 8 , wherein the composite material is biodegradable.

10. The method of claim 9 , wherein the zwitterionic moiety is present in the polymer at a density from about 0.05 mol % to about 10 mol %.

Assignees

• Univ Massachusetts

Inventors

• Song Jie
• Liu Pingsheng

Classifications

• A61K38/18 Primary

  Growth factors; Growth regulators · CPC title

• A61K38/30

  Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 {(insulin-like growth factor binding protein A61K38/1754)} · CPC title

• A61L27/18

  obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds · CPC title

• A61L27/58 Primary

  Materials at least partially resorbable by the body · CPC title

• A61K38/1875

  Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor · CPC title